NO2447254T3 - - Google Patents

Info

Publication number
NO2447254T3
NO2447254T3 NO10792183A NO10792183A NO2447254T3 NO 2447254 T3 NO2447254 T3 NO 2447254T3 NO 10792183 A NO10792183 A NO 10792183A NO 10792183 A NO10792183 A NO 10792183A NO 2447254 T3 NO2447254 T3 NO 2447254T3
Authority
NO
Norway
Application number
NO10792183A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43386634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2447254(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2447254T3 publication Critical patent/NO2447254T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
NO10792183A 2009-06-26 2010-06-25 NO2447254T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2009151727 2009-06-26
JP2009151728 2009-06-26
JP2009151729 2009-06-26
PCT/JP2010/060798 WO2010150865A1 (ja) 2009-06-26 2010-06-25 結晶

Publications (1)

Publication Number Publication Date
NO2447254T3 true NO2447254T3 (pl) 2018-05-05

Family

ID=43386634

Family Applications (2)

Application Number Title Priority Date Filing Date
NO10792183A NO2447254T3 (pl) 2009-06-26 2010-06-25
NO2018015C NO2018015I1 (no) 2009-06-26 2018-04-23 2-{4-[N-(5,6-difenylpyrazin-2-yl)-N-isopropylamino]butyloksy}-N-(metylsulfonyl)acetamid

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO2018015C NO2018015I1 (no) 2009-06-26 2018-04-23 2-{4-[N-(5,6-difenylpyrazin-2-yl)-N-isopropylamino]butyloksy}-N-(metylsulfonyl)acetamid

Country Status (33)

Country Link
US (4) US8791122B2 (pl)
EP (3) EP3689855A1 (pl)
JP (1) JPWO2010150865A1 (pl)
KR (4) KR102705198B1 (pl)
CN (2) CN104326991A (pl)
AR (1) AR077242A1 (pl)
AU (1) AU2010263569B2 (pl)
BR (2) BRPI1015936B1 (pl)
CA (1) CA2764475C (pl)
CL (1) CL2011003264A1 (pl)
CO (1) CO6430432A2 (pl)
CY (3) CY1119788T1 (pl)
DK (2) DK2447254T3 (pl)
ES (2) ES2660007T3 (pl)
HK (1) HK1244788A1 (pl)
HR (2) HRP20180171T1 (pl)
HU (3) HUE048467T2 (pl)
IL (3) IL216928A (pl)
LT (3) LT3275871T (pl)
MA (1) MA33637B1 (pl)
MX (2) MX346318B (pl)
MY (1) MY186531A (pl)
NO (2) NO2447254T3 (pl)
NZ (1) NZ597352A (pl)
PH (2) PH12015502824A1 (pl)
PL (2) PL2447254T3 (pl)
PT (2) PT2447254T (pl)
RU (1) RU2556206C3 (pl)
SG (2) SG176915A1 (pl)
SI (2) SI3275871T1 (pl)
TW (1) TWI531565B (pl)
WO (1) WO2010150865A1 (pl)
ZA (1) ZA201109099B (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2246336T3 (da) * 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
MY163762A (en) 2008-07-23 2017-10-31 Toray Industries Therapeutic agent for chronic renal failure
CN106279047B (zh) 2015-05-13 2019-05-03 普济生物科技（台州）有限公司 一种前列环素受体激动剂的制备方法
WO2016193994A1 (en) 2015-05-29 2016-12-08 Megafine Pharma (P) Ltd. Amorphous selexipag and process for preparation thereof
WO2017029594A1 (en) * 2015-08-17 2017-02-23 Dr. Reddy's Laboratories Limited Processes for preparation of selexipag and its amorphous form
EP3344607B1 (en) 2015-09-03 2019-11-06 Teva Pharmaceuticals International GmbH Solid state forms of selexipag
WO2017042731A1 (en) 2015-09-10 2017-03-16 Lupin Limited Amorphous form of selexipag and solid dispersion thereof
WO2017042828A2 (en) * 2015-09-10 2017-03-16 Megafine Pharma (P) Ltd. Process for the preparation of selexipag and intermediates thereof
AU2016366073B2 (en) * 2015-12-02 2021-08-26 Nippon Shinyaku Co., Ltd. Pharmaceutical composition containing 2-{4-[N-(5,6- diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N- (methylsulfonyl)acetamide
WO2017109772A1 (en) * 2015-12-20 2017-06-29 Mapi Pharma Ltd. Amorphous form of selexipag
EP3192502A1 (en) 2016-01-15 2017-07-19 Sandoz Ag Pharmaceutical composition of selexipag
ES2911531T3 (es) 2016-04-01 2022-05-19 Honour R&D Procedimiento para la preparación de los derivados de difenilpirazina
CN105949135A (zh) * 2016-05-10 2016-09-21 湖南欧亚生物有限公司 一种赛乐西帕的合成方法
EP3481807A4 (en) * 2016-07-05 2020-01-15 Maithri Drugs Private Limited NEW PROCESS FOR THE PREPARATION OF 2- {4 - [(5,6-DIPHENYL PYRAZIN-2-YL) (ISOPROPYL) AMINO] BUTOXY} -N- (METHYLSULFONYL) ACETAMIDE AND NEW POLYMORPHS THEREOF
WO2018015974A1 (en) 2016-07-20 2018-01-25 Mylan Laboratories Limited Polymorphic forms and amorphous solid dispersion of selexipag
WO2018022704A1 (en) 2016-07-26 2018-02-01 Teva Pharmaceuticals International Gmbh Crystalline form vi of selexipag
WO2018078383A1 (en) 2016-10-27 2018-05-03 Cipla Limited Pharmaceutical composition comprising amorphous selexipag
CN108069914A (zh) * 2016-11-17 2018-05-25 江苏艾立康药业股份有限公司 一种西里帕格晶型的制备方法
CA3046025A1 (en) 2016-12-14 2018-06-21 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
EP3335699A1 (en) 2016-12-15 2018-06-20 H e x a l Aktiengesellschaft Selexipag formulation in liquisolid system
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
EP3658187A1 (en) 2017-07-27 2020-06-03 Allergan, Inc. Prostacyclin receptor agonists for reduction of body fat
TWI801421B (zh) 2017-09-28 2023-05-11 日商日本新藥股份有限公司 結晶
BR112020008940A2 (pt) 2017-11-16 2020-10-20 Nippon Shinyaku Co., Ltd. preparação de liberação controlada
US10407396B2 (en) 2017-11-16 2019-09-10 Apotex Inc. Crystalline form of selexipag
JP2021512902A (ja) 2018-02-07 2021-05-20 メッドシャイン ディスカバリー インコーポレイテッド プロスタサイクリン受容体アゴニスト
US20200397700A1 (en) * 2018-02-21 2020-12-24 Nippon Shinyaku Co., Ltd. Granular composition, production method for granular composition, and dissolution property improvement method for granular composition
CN109125325B (zh) 2018-09-25 2021-05-25 中国人民解放军总医院 前列环素受体激动剂的医药用途
EP3705115B1 (en) 2019-03-07 2021-06-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Composition containing selexipag
JP2022532076A (ja) 2019-05-06 2022-07-13 アクテリオン ファーマシューティカルズ リミテッド サルコイドーシス関連肺高血圧症の治療方法
JP2022533394A (ja) 2019-05-21 2022-07-22 アクテリオン ファーマシューティカルズ リミテッド 肺動脈性肺高血圧症の治療を受けている患者のセレキシパグへの移行方法
US20220323437A1 (en) 2019-06-11 2022-10-13 Actelion Pharmaceuticals Ltd Methods for treating pulmonary arterial hypertension
WO2021023271A1 (zh) * 2019-08-06 2021-02-11 南京明德新药研发有限公司 作为前列环素受体激动剂的化合物的晶型及其制备方法
CA3154802A1 (en) 2019-10-23 2021-04-29 Marc Patrik SCHRADER Pharmaceutical composition comprising selexipag
JP2023504115A (ja) 2019-11-29 2023-02-01 アクテリオン ファーマシューティカルズ リミテッド 肺動脈性肺高血圧症の治療方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン
WO2021152060A1 (en) 2020-01-31 2021-08-05 Actelion Pharmaceuticals Ltd Controlled release selexipag composition
EP4100013A1 (en) 2020-02-03 2022-12-14 Actelion Pharmaceuticals Ltd Methods of treating and assessing pulmonary arterial hypertension with selexipag
CN112500358B (zh) * 2020-11-18 2022-03-15 江苏豪森药业集团有限公司 赛乐西帕晶型及其制备方法
WO2022106621A1 (en) 2020-11-20 2022-05-27 Actelion Pharmaceuticals Ltd Selexipag for use via intracolonic administration
TW202239408A (zh) 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物
TW202241425A (zh) 2021-01-29 2022-11-01 瑞士商艾克泰聯製藥有限公司 用於製造二苯基吡𠯤衍生物之程序
WO2022238375A1 (en) 2021-05-11 2022-11-17 Actelion Pharmaceuticals Ltd Methods of treating pulmonary hypertension
WO2023131608A1 (en) 2022-01-04 2023-07-13 Actelion Pharmaceuticals Ltd Controlled release compositions
WO2023214059A1 (en) 2022-05-06 2023-11-09 Actelion Pharmaceuticals Ltd Diphenylpyrazine compounds as prodrugs
WO2024017964A1 (en) 2022-07-20 2024-01-25 Actelion Pharmaceuticals Ltd Injectable pharmaceutical composition comprising a diphenylpyrazine derivative
WO2024133620A1 (en) 2022-12-22 2024-06-27 Actelion Pharmaceuticals Ltd In vitro dissolution test
WO2024142718A1 (ja) * 2022-12-27 2024-07-04 株式会社トクヤマ セレキシパグのｉ型結晶の製造方法
EP4393474A1 (en) * 2022-12-28 2024-07-03 Sanovel Ilac Sanayi Ve Ticaret A.S. A formulation comprising selexipag
EP4393476A1 (en) * 2022-12-28 2024-07-03 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet formulation comprising selexipag
EP4393475A1 (en) 2022-12-28 2024-07-03 Sanovel Ilac Sanayi Ve Ticaret A.S. Formulations comprising selexipag
WO2024194449A1 (en) 2023-03-23 2024-09-26 Actelion Pharmaceuticals Ltd Pharmaceutical composition comprising a diphenylpyrazine derivative

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030092760A1 (en) 2001-03-12 2003-05-15 Toray Industries, Inc. Therapeutic agent for renal failure
EP1106176B1 (en) 1999-05-10 2008-06-18 Toray Industries, Inc. Remedies for renal failure
DE60102106T2 (de) 2000-08-03 2004-07-15 Pfizer Products Inc., Groton Diazacyclooctanverbindungen und ihre therapeutische Verwendung
WO2002085412A1 (fr) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Inhibiteurs de la fibrose des tissus
TWI316055B (pl) 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
EP1642584A1 (en) 2003-06-25 2006-04-05 Cardiovascular Institute, Ltd External preparation for improving coital function
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
DK2246336T3 (da) 2008-02-28 2020-07-20 Nippon Shinyaku Co Ltd Fibroseinhibitor
WO2009154246A1 (ja) 2008-06-19 2009-12-23 日本新薬株式会社 勃起不全治療剤
WO2009157396A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 脊柱管狭窄症治療剤
CN102065864B (zh) 2008-06-23 2012-11-21 日本新药株式会社 炎性肠病治疗剂
WO2009157397A1 (ja) 2008-06-23 2009-12-30 日本新薬株式会社 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤
MY163762A (en) 2008-07-23 2017-10-31 Toray Industries Therapeutic agent for chronic renal failure
BRPI0918134B1 (pt) 2008-09-10 2019-02-12 Kaken Pharmaceutical Co., Ltd Derivado de prostaglandina i2

Also Published As

Publication number Publication date
ZA201109099B (en) 2012-08-29
RU2556206C3 (ru) 2021-06-15
EP2447254A4 (en) 2012-12-19
CA2764475A1 (en) 2010-12-29
BRPI1015936B1 (pt) 2021-07-13
CN102459198A (zh) 2012-05-16
ES2660007T3 (es) 2018-03-20
HUS1800015I1 (hu) 2018-05-28
US20140155414A1 (en) 2014-06-05
MA33637B1 (fr) 2012-10-01
WO2010150865A1 (ja) 2010-12-29
LT3275871T (lt) 2020-05-11
IL216928A0 (en) 2012-02-29
CA2764475C (en) 2017-04-25
EP3275871B1 (en) 2020-01-15
US9284280B2 (en) 2016-03-15
KR20120109457A (ko) 2012-10-08
CY2018011I1 (el) 2018-09-05
RU2556206C2 (ru) 2015-07-10
US8791122B2 (en) 2014-07-29
MY186531A (en) 2021-07-25
SI3275871T1 (sl) 2020-06-30
US20140148469A1 (en) 2014-05-29
US20120101276A1 (en) 2012-04-26
IL243293A0 (en) 2016-02-29
CO6430432A2 (es) 2012-04-30
PT3275871T (pt) 2020-04-21
LTPA2018008I1 (lt) 2018-05-10
NO2018015I1 (no) 2018-04-23
DK3275871T3 (da) 2020-04-06
AU2010263569B2 (en) 2016-08-18
HUE036721T2 (hu) 2018-07-30
DK2447254T3 (en) 2018-01-15
AU2010263569A1 (en) 2012-02-02
CY1119788T1 (el) 2018-06-27
JPWO2010150865A1 (ja) 2012-12-10
RU2012102678A (ru) 2013-08-10
US9340516B2 (en) 2016-05-17
HK1244788A1 (zh) 2018-08-17
KR102669213B1 (ko) 2024-05-28
EP2447254B1 (en) 2017-12-06
TWI531565B (zh) 2016-05-01
KR20240090717A (ko) 2024-06-21
PL3275871T3 (pl) 2020-07-27
PH12015502825B1 (en) 2017-12-11
TW201111352A (en) 2011-04-01
MX2011013471A (es) 2012-01-30
EP2447254A1 (en) 2012-05-02
BR122021005510B1 (pt) 2022-01-11
NZ597352A (en) 2013-01-25
US8791122C1 (pl) 2014-07-29
CY2018011I2 (el) 2018-09-05
LTC2447254I2 (lt) 2022-04-25
PH12015502825A1 (en) 2017-12-11
KR20240090716A (ko) 2024-06-21
EP3275871A1 (en) 2018-01-31
LT2447254T (lt) 2018-01-10
SI2447254T1 (en) 2018-03-30
KR20170024165A (ko) 2017-03-06
HRP20200539T1 (hr) 2020-07-10
CL2011003264A1 (es) 2012-07-06
PT2447254T (pt) 2018-01-04
HUE048467T2 (hu) 2020-07-28
IL243287B (en) 2021-04-29
PH12015502824A1 (en) 2017-05-29
AR077242A1 (es) 2011-08-10
CN102459198B (zh) 2014-09-24
MX346318B (es) 2017-03-15
CY1122893T1 (el) 2021-05-05
EP3689855A1 (en) 2020-08-05
IL243287A0 (en) 2016-02-29
ES2797124T3 (es) 2020-12-01
SG176915A1 (en) 2012-01-30
US9440931B2 (en) 2016-09-13
KR102705198B1 (ko) 2024-09-11
BRPI1015936A2 (pt) 2016-08-16
IL216928A (en) 2016-10-31
HRP20180171T1 (hr) 2018-03-09
CN104326991A (zh) 2015-02-04
PL2447254T3 (pl) 2018-05-30
SG10201403313WA (en) 2014-10-30
US20150266830A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
BR112012008267A2 (pl)
BR112012003062A2 (pl)
BR112012008195A2 (pl)
BR112012000607A2 (pl)
BRPI0925311A2 (pl)
BR112012003080A2 (pl)
BR112012000665A2 (pl)
BR112012003853A2 (pl)
BR112012009446A2 (pl)
BR112012009703A2 (pl)
BR112012007656A2 (pl)
BR112012001263A2 (pl)
BR112012002627A2 (pl)
BR112012007672A2 (pl)
BR112012007654A2 (pl)
BR112012005951A2 (pl)
BR112012000255A2 (pl)
BR112012009404A2 (pl)
BR112012000156A2 (pl)
BRPI0924617A2 (pl)
BRPI1009566A2 (pl)
BRPI0925022A2 (pl)
BR112012007671A2 (pl)
BR112012000689A2 (pl)
BR112012003654A2 (pl)